Trends in reported AIDS defining illnesses (ADIs) among participants in a universal antiretroviral therapy program: an observational study
- PMID: 21892955
- PMCID: PMC3180248
- DOI: 10.1186/1742-6405-8-31
Trends in reported AIDS defining illnesses (ADIs) among participants in a universal antiretroviral therapy program: an observational study
Abstract
Background: We examined trends in AIDS-defining illnesses (ADIs) among individuals receiving highly active antiretroviral therapy (HAART) in British Columbia (BC), Canada to determine whether declines in ADIs could be contributing to previously observed improvements in life-expectancy among HAART patients in BC since 1996.
Methods: HAART-naïve individuals aged ≥ 18 years who initiated treatment in BC each of the following time-periods 1996 - 1998; 1999 - 2001; 2002 - 2004; 2005 - 2007 were included. The proportion of participants with reported ADIs were examined for each time period and trends were analyzed using the Cochran-Armitage Trend Test. Cox proportional hazards models were used to examine factors associated with ADIs.
Results: A total of 3721 individuals (81% male) initiated HAART during the study period. A total of 251 reports of ADIs were received from 214 unique patients. These occurred in a median of 4 months (IQR = 1-19 months) from HAART initiation. The proportion of individuals with a reported ADI did not change significantly from 4.6% in the earliest time period to 5.8% in the latest period (p = 0.181 for test of trend). There were no significant declines in any specific ADI over the study period. Multivariable Cox models found that individuals initiating HAART during 2002-04 were at an increased risk of ADIs (AHR = 1.55; 95% CI 1.04-2.32) in comparison to 1996 - 98, but there were no significant differences in other time periods.
Conclusions: Trends in reported ADIs among individuals receiving HAART since 1996 in BC do not appear to parallel improvements in life-expectancy over the same period.
Similar articles
-
Impact of highly active antiretroviral therapy on individual AIDS-defining illness incidence and survival in Australia.J Acquir Immune Defic Syndr. 2002 Apr 1;29(4):388-95. doi: 10.1097/00126334-200204010-00010. J Acquir Immune Defic Syndr. 2002. PMID: 11917244
-
Changes to AIDS dementia complex in the era of highly active antiretroviral therapy.AIDS. 1999 Jul 9;13(10):1249-53. doi: 10.1097/00002030-199907090-00015. AIDS. 1999. PMID: 10416530
-
Physicians' patient base composition and mortality among people living with HIV who initiated antiretroviral therapy in a universal care setting.BMJ Open. 2019 Mar 20;9(3):e023957. doi: 10.1136/bmjopen-2018-023957. BMJ Open. 2019. PMID: 30898806 Free PMC article.
-
AIDS incidence and AIDS-related mortality in British Columbia, Canada, between 1981 and 2013: a retrospective study.Lancet HIV. 2015 Mar;2(3):e92-7. doi: 10.1016/S2352-3018(15)00017-X. Lancet HIV. 2015. PMID: 25780802 Free PMC article.
-
Opportunistic infections and other AIDS-defining illnesses in Poland in 2000-2002.Infection. 2006 Aug;34(4):196-200. doi: 10.1007/s15010-006-5030-y. Infection. 2006. PMID: 16896577
Cited by
-
Changes in Parents' COVID-19 Vaccine Hesitancy for Children Aged 3-17 Years before and after the Rollout of the National Childhood COVID-19 Vaccination Program in China: Repeated Cross-Sectional Surveys.Vaccines (Basel). 2022 Sep 6;10(9):1478. doi: 10.3390/vaccines10091478. Vaccines (Basel). 2022. PMID: 36146556 Free PMC article.
-
Differences in intention to receive clinician-collected and self-collected samples for HPV DNA testing and its determinants between heterosexual males and females in Hong Kong, China: findings of a territory-wide household survey.BMC Med. 2024 Dec 2;22(1):569. doi: 10.1186/s12916-024-03788-z. BMC Med. 2024. PMID: 39623384 Free PMC article.
References
-
- Dore GJ, Li Y, McDonald A, Ree H, Kaldo JM. Impact of Highly Active Antiretroviral Therapy on Individual AIDS-Defining Illness Incidence and Survival in Australia. J Acquir Immune Defic Syndr. 2002;29:29–395. - PubMed
-
- Detels R, Tarwater P, Phair JP, Margolick J, Riddler SA, Munoz A. Multicenter AIDS Cohort Study. Effectiveness of potent antiretroviral therapies on the incidence of opportunistic infections before and after AIDS diagnosis. AIDS. 2001;15:347–355. doi: 10.1097/00002030-200102160-00008. - DOI - PubMed
-
- Crum NF, Riffenburgh RH, Wegner S, Agan BK, Tasker SA, Spooner KM. et al.Comparisons of Causes of Death and Mortality Rates Among HIV-Infected Persons: Analysis of the Pre-, Early, and Late HAART (Highly Active Antiretroviral Therapy) Eras. J Acquir Immune Defic Syndr. 2006;41:194–200. doi: 10.1097/01.qai.0000179459.31562.16. - DOI - PubMed
LinkOut - more resources
Full Text Sources